Tissue plasminogen activator antibodies and methods of use
View Patent ↗A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.
1. An antibody that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant to inhibit degradation of human fibrin clots, wherein said antibody having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, and wherein the amino acid sequence of said TPA mutant has at least 65% identity to SEQ ID NO: 1 or SEQ ID NO: 2; and wherein said antibody is a monoclonal antibody identified as TPAi-14 (ECACC accession number 18042001) or TPAi-23 (ECACC accession number 18042002) that selectively inhibits fibrin-augmented plasminogen activation.
2. The antibody of claim 1 , wherein the antibody does not affect TPA amidolytic activity or non-fibrin-dependent activation.
3. The antibody of claim 1 wherein the amino acid sequence of human TPA is SEQ ID NO: 1 or SEQ ID NO: 2.
4. The antibody of claim 1 , wherein monoclonal antibody TPAi-14 and TPAi-23 bind to different epitopes of the TPA.
5. A monoclonal antibody identified as TPAi-14 (ECACC accession number 18042001) or TPAi-23 (ECACC accession number 18042002) that selectively inhibits fibrin-augmented plasminogen activation.
6. A method for treating TPA-induced hemorrhage in a patient in need of such treatment, which comprises administering to said patient an effective amount of the antibody of claim 1 , wherein said antibody selectively inhibits fibrin-augmented plasminogen activation in said patient.
7. The method of claim 6 , wherein the patient suffers from ischemic stroke.
8. The method of claim 6 , wherein the patient suffers from acute myocardial infarction.
9. The method of claim 6 , wherein the antibody reduces TPA-induced cerebral hemorrhage and surgical bleeding.
10. The method of claim 6 , wherein the antibody inhibits fibrinolysis induced by TPA.
11. The method of claim 10 , wherein said antibody inhibits the initiation of fibrinolysis.
12. The method of claim 6 , wherein said antibody is identified as TPAi-14.
13. The method of claim 6 , wherein said antibody is identified as TPAi-23.
14. The method of claim 6 , wherein TPAi-14 and TPAi23 are used together and synergistically inhibit fibrinolysis induced by TPA.
15. The method of claim 6 , wherein the TPA-induced hemorrhage comprises systemic bleeding, brain hemorrhage, and/or stroke.